One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Zimmer Biomet Holdings logo
Zimmer Biomet Holdings ZBH
$ 96.52 -1.97%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Zimmer Biomet Holdings Financial Statements 2025-2006 | ZBH

Annual Financial Statements Zimmer Biomet Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Market Cap

16.3 B 21.8 B 26.9 B 25.7 B 25.7 B 30.7 B 31 B 22.1 B 25.4 B 23.1 B 18.6 B 18.9 B 15.8 B 13 B 11.4 B 10.5 B 9.54 B 16 B 20.1 B -

Shares

198 M 203 M 209 M 210 M 209 M 207 M 205 M 204 M 202 M 200 M 187 M 169 M 170 M 175 M 188 M 200 M 215 M 227 M 236 M -

Historical Prices

82.3 107 129 123 123 148 143 98.2 113 96.1 94.7 104 84.4 59.7 47.4 52.6 44.4 70.3 85.5 59.3

Net Income

705 M 904 M 1.02 B 231 M 402 M -139 M 1.13 B -379 M 1.81 B 306 M 147 M - 761 M 755 M 761 M 597 M 717 M 849 M 773 M -

Revenue

8.23 B 7.68 B 7.39 B 6.94 B 6.83 B 6.13 B 7.98 B 7.93 B 7.82 B 7.68 B 6 B - 4.62 B 4.47 B 4.45 B - - - - -

Cost of Revenue

2.49 B 2.19 B 2.08 B 2.02 B 1.96 B 1.82 B 1.94 B 2.27 B 2.13 B 2.38 B - - - - - 1.01 B 991 M 997 M 876 M -

Gross Profit

- - - - - - 5.73 B 5.66 B 5.69 B 5.3 B 4.2 B - 3.34 B 3.35 B 3.33 B 3.21 B 3.1 B 3.12 B 3.02 B -

Operating Income

1.1 B 1.29 B 1.28 B 696 M 860 M 83.1 M 1.11 B 33.8 M 799 M 821 M 467 M 1.04 B 1.07 B 1.05 B 1.02 B 917 M 1.02 B 1.09 B 1.13 B -

Interest Expense

25.5 M -31.1 M -9.3 M -128 M 12.2 M 23.8 M -4.9 M -15.6 M -9.4 M -66.5 M -36.9 M -46.7 M - - - - - - - -

EBITDA

2.19 B 2.28 B 2.23 B 1.62 B 1.8 B 982 M 1.85 B 1.74 B 1.95 B 1.65 B 1.27 B - 1.17 B 1.21 B 1.46 B 1.26 B 1.36 B 1.37 B 1.36 B -

Operating Expenses

- - - - - - 4.46 B 4.51 B 4.34 B 4.21 B 3.27 B - 2.18 B 2.14 B 2.23 B 2.29 B 2.09 B 2.03 B 1.89 B -

General and Administrative Expenses

3.26 B 2.93 B 2.84 B 2.76 B 2.84 B 2.71 B 3.34 B 3.38 B 3.37 B 3.28 B 2.66 B - 1.97 B 1.91 B 1.99 B 1.76 B 1.73 B 1.7 B 1.52 B -

All numbers in USD currency

Quarterly Income Statement Zimmer Biomet Holdings

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2 2010-Q1 2009-Q3 2009-Q2

Shares

192 M 195 M 198 M 198 M 199 M 202 M 206 M 205 M 209 M 209 M 209 M - 210 M 210 M 209 M - 209 M 209 M 208 M - 207 M 207 M 206 M - 205 M 205 M 204 M - 204 M 203 M 203 M - 202 M 202 M 201 M - 200 M 199 M 200 M - 204 M 173 M 170 M - 169 M 168 M 169 M - 170 M 169 M 169 M - 174 M 175 M 177 M - 188 M 192 M 193 M 199 M 202 M 203 M 214 M 215 M

Net Income

198 M 238 M 231 M 153 M 182 M 249 M 243 M 172 M 163 M 210 M 232 M - 194 M 154 M 14.2 M - 146 M 142 M 198 M 334 M 242 M -207 M -508 M 321 M 431 M 134 M 246 M -901 M 162 M 185 M 175 M 1.23 B 98.8 M 184 M 299 M 69.6 M 159 M -31.3 M 109 M 127 M 22.2 M -174 M 171 M 154 M 173 M 172 M 221 M 236 M 154 M 152 M 219 M 153 M 178 M 214 M 210 M 157 M 192 M 204 M 209 M 191 M 166 M 205 M 150 M 210 M

Revenue

2.18 B 2.09 B 2 B 2.08 B 1.91 B 1.82 B 1.94 B 1.89 B 1.75 B 1.87 B 1.83 B - 1.67 B 1.78 B 1.66 B - 1.69 B 2.03 B 1.6 B 2.09 B 1.93 B 1.23 B 1.78 B 2.13 B 1.89 B 1.99 B 1.98 B 2.07 B 1.84 B 2.01 B 2.02 B 2.07 B 1.81 B 1.95 B 1.97 B - - - - - - - - - - - - - - - - - - - - - - - 1.12 B - - - - -

Cost of Revenue

636 M 576 M 559 M 592 M 550 M 539 M 554 M 512 M 519 M 526 M 501 M - 488 M 511 M 500 M - 491 M 582 M 436 M - 569 M 424 M 487 M - 536 M 581 M 553 M - 529 M 584 M 576 M - 501 M - - - - - - - - - - - - - - - - - - - - - - - - - 279 M 219 M 251 M 268 M 249 M 237 M

Gross Profit

- - - - - - - - - - - - - - - - - - - 1.29 B 1.21 B 654 M 1.15 B 1.4 B 1.21 B 1.26 B 1.28 B 1.34 B 1.16 B 1.27 B 1.29 B 1.33 B 1.16 B 1.27 B 1.31 B 1.25 B 1.19 B 1.16 B 1.14 B 1.1 B 1.09 B 840 M 829 M 889 M 790 M 851 M 858 M 900 M 746 M 846 M 846 M 882 M 770 M 843 M 852 M 864 M 780 M 850 M 837 M 746 M 807 M 794 M 726 M 783 M

Operating Income

326 M 373 M 351 M 300 M 292 M 280 M 351 M 266 M 267 M 330 M 327 M - 245 M 281 M 198 M - 243 M 220 M 259 M - 299 M -172 M -456 M - 246 M 205 M 350 M - 223 M 296 M 305 M - 211 M 280 M 348 M - 196 M 202 M 246 M - 116 M -132 M 270 M - 255 M 261 M 300 M - 212 M 210 M 298 M - 249 M 302 M 296 M - 267 M 259 M 297 M 272 M 228 M 294 M 204 M 296 M

Interest Expense

1.9 M -3 M 3.3 M 3.9 M 2.9 M 5.1 M 2 M -100 K 3.8 M -1.2 M 7.7 M - -25.4 M -42.6 M -56.1 M - 300 K 8.1 M 7.7 M - 10.6 M 3.8 M 3 M - -4.4 M -4.7 M -500 K - -2.2 M -2.9 M -3.6 M - -2.3 M -1.7 M -500 K - -1.1 M -3.8 M -3.8 M - 4.3 M - - - -12.1 M - - - - - - - - - - - -11.7 M -9.8 M -11 M - - - - -

EBITDA

867 M 643 M 1.16 B 826 M 547 M 530 M 595 M 504 M 412 M 468 M 559 M - 377 M 414 M 432 M - 948 M 375 M 494 M - 1.07 B 337 M -203 M - 998 M 705 M 598 M - 1.01 B 821 M 568 M - 1.01 B 812 M 616 M - 983 M 701 M 492 M - 544 M 56.5 M 359 M - 538 M 453 M 401 M - 480 M 387 M 383 M - 522 M 492 M 392 M - 532 M 434 M 383 M 521 M 394 M 379 M 454 M 458 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1.73 B 1.66 B - 1.65 B 1.3 B 864 M - 851 M 590 M 558 M - 534 M 636 M 548 M - 520 M 541 M 556 M - 513 M 590 M 539 M 474 M 579 M 500 M 522 M 487 M

General and Administrative Expenses

899 M 850 M 811 M 815 M 759 M 710 M 737 M 736 M 675 M 726 M 716 M - 655 M 695 M 684 M - 684 M 817 M 657 M - 790 M 665 M 829 M - 826 M 839 M 796 M - 788 M 791 M 802 M - 712 M 752 M 758 M - 728 M 732 M 717 M - 692 M 444 M 424 M - 423 M 436 M 444 M - 438 M 458 M 461 M - 430 M 453 M 463 M - 444 M 470 M 458 M 412 M 437 M 447 M 413 M 432 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Zimmer Biomet Holdings ZBH
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Zimmer Biomet Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.7 -1.12 % $ 384 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 71.03 0.41 % $ 2.41 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 1.78 % $ 3.4 M usaUSA
AxoGen AxoGen
AXGN
$ 38.31 0.64 % $ 1.76 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 6.78 0.37 % $ 1.68 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 47.96 -2.48 % $ 1.49 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.05 -1.04 % $ 256 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 14.66 1.66 % $ 525 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Globus Medical Globus Medical
GMED
$ 81.12 -0.36 % $ 11 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.07 1.34 % $ 925 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.77 -1.43 % $ 890 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.41 1.69 % $ 99 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.12 -4.69 % $ 14.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.76 -0.12 % $ 1.09 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.54 -0.01 % $ 4.4 B usaUSA
Inogen Inogen
INGN
$ 7.05 -0.77 % $ 188 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.98 0.68 % $ 8.8 B usaUSA